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Previously, clinicians worked with antipsychotic drugs that almost invariably
caused extrapyramidal side effects (EPS) at the dose at which they were
clinically effective. By definition, all newer generation atypical antipsychotic
agents are significantly better than conventional agents with regard to EPS;
i.e., they are clinically effective at doses at which they do not cause EPS. This
EPS advantage of atypical antipsychotics translates into several important
clinical benefits, including better negative symptom efficacy, lesser dysphoria,
less impaired cognition, and a lower risk of tardive dyskinesia; in fact, this
“EPS advantage” is the principal basis of the many clinical advantages pro-
vided by the class of atypical antipsychotics. While all atypical agents share
this “EPS advantage,” there are important differences between these agents
with regard to the ease and consistency with which this EPS advantage can
be realized. Pharmacologically, different atypical antipsychotics differ; these
differences translate into differences in their side effect profiles. Five atypical
antipsychotics are currently available: clozapine, risperidone, olanzapine, que-
tiapine, and ziprasidone. Meaningful differences between these agents with re-
gard to weight gain, sedation, anticholinergic side effects, cardiovascular issues,
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endocrine side effects, hepatic and sexual issues, will be considered and their
clinical implications discussed.
KEY WORDS: antipsychotics; side effects; treatment; schizophrenia; pharmacology.
INTRODUCTION
Approximately forty antipsychotic agents are available around the
world, of which twenty are approved for use in the U.S.A. These agents,
primarily utilized for the treatment of schizophrenia and other psy-
chotic disorders, first became available fifty years ago. Originally these
agents were referred to as major tranquilizers because of their
significant sedative properties or more commonly as neuroleptics be-
cause of their propensity to cause parkinsonian side effects. In fact,
these agents were identified as much by this extrapyramidal side effect
(EPS) as by their efficacy in treating psychotic symptoms and until re-
cently, EPS were considered an unavoidable byproduct of antipsychotic
treatment. Over the past decade, five atypical or newer generation an-
tipsychotic agents have become available in the U.S.A.; these agents
are principally distinguished by their at-least equivalent antipsychotic
efficacy to the older-generation conventional neuroleptics with a much
lower propensity to cause EPS (Figure 1).
Extrapyramidal side effects have a pervasive negative impact on
treatment. Acute dystonic reactions are uncomfortable and frightening
to the patient, and lead to early discontinuation of therapy and worse
long-term outcome. ‘Parkinsonian’ bradykinesia and rigidity contribute
secondary negative symptoms to the illness by reducing facial expres-
sion, vocal intonation, and affective responsiveness (1). Early develop-
ment of these motor side effects has been correlated with subsequent
development of tardive dyskinesia (2). Akathisia may be experienced
by patients as restlessness, anxiety, agitation, insomnia, or generalized
discomfort. Akathisia is frequently overlooked among medication side
effects by clinicians and patients alike, but is strongly associated with
premature termination of treatment (3). The adverse effect of EPS on
cognitive function has only recently been recognized (4). EPS are now
known to have a direct, adverse effect on cognition. In addition to this
direct effect, EPS are commonly treated with anticholinergic medica-
tions, which further impair cognitive function.
The lower propensity of the five newer generation “atypical” antipsy-
chotics to cause EPS is therefore associated with multiple benefits,
including a broader spectrum of efficacy (greater improvement in
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FIGURE 1. Antipsychotics in the United States—historical
perspective.
negative, cognitive, and depressive symptoms), a lower risk of tardive
dyskinesia (about a 90% reduction over 1–2 years), and improved com-
pliance (Figure 2) (5). These advantages of the newer generation “atyp-
ical” agents over the older “conventional” neuroleptics explain their
FIGURE 2. Benefits of atypical antipsychotics: Relationship
to achieve antipsychotic effect without EPS.
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greater utilization by clinicians in the U.S.A., where they collectively
constitute approximately 80% of all antipsychotics prescribed.
The Newer Generation “Atypical” Antipsychotics:
Are They All the Same?
Five newer generation antipsychotics are currently available in the
U.S.A.: clozapine, risperidone, olanzapine, quetiapine, and ziprasidone
(in order of their introduction, Figure 1). As noted above, this group
of agents is clinically distinguished from the older “neuroleptics” by
at least equivalent antipsychotic potency, broader spectrum of efficacy
(negative, cognitive, and mood symptoms), and a lower risk of EPS and
tardive dyskinesia (Figure 2). Clozapine, the first among these agents
to become available, was additionally found to be superior in efficacy to
conventional “neuroleptics” in treating otherwise refractory schizophre-
nia patients (6–8). However, because of its many significant adverse
effects (Table 3) and the need for periodic hematological monitoring, its
use is reserved for otherwise treatment-refractory patients.
Because of an overall better safety/tolerability profile than cloza-
pine, the other four agents (risperidone, olanzapine, quetiapine, and
ziprasidone) are often referred to as “first-line atypical antipsychotics.”
A number of studies have been undertaken to determine if there are
significant differences in efficacy, speed of response, and stability of
remission among these medications. To date, no clear pattern of supe-
rior efficacy among these agents has emerged (9–14); in fact, each of
these “first-line atypical antipsychotic drugs” appears to have equiv-
alent efficacy in reducing overall psychopathology as also severity of
specific symptom domains (positive, negative, affective) in patients with
schizophrenia. Appropriate dosing with each of these agents (Table 4)
is critical to optimizing efficacy.
While sharing the clinical attributes of a broader spectrum of effi-
cacy and lower risk of EPS and tardive dyskinesia, these four agents
are chemically and pharmacologically distinct from one another, and
each consequently has a unique side effect profile. The remainder of
this paper explores the relationship between the neuropharmacolog-
ical profiles of currently available atypical antipsychotic agents and
their clinical attributes (particularly, their side effects). A strategy to
incorporate this information while selecting between different atypical
antipsychotic agents is then summarized.
There are similarities and differences between the receptor-blocking
profiles of conventional and atypical antipsychotics and between dif-
ferent atypical antipsychotics. There are also known differences in the
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TABLE 1
Pharmacological Profile of Atypical Antipsychotics
Clozapine: several properties (D-1, D-2, D-3, D-4, 5HT-2A, 5HT-2C,
5HT-3, ACh, H-1, NE)
Risperidone: D-2 + 5HT-2A + 5HT-2C + alpha-1 NE
Olanzapine: D-2 + 5HT-2A + 5HT-2C + (alpha-1 NE) + (M-1) + H-1
Quetiapine: D-2 + 5HT-2A + alpha-1 NE + H-1
Ziprasidone: D-2 + 5HT-2A + (increased NE, 5HT, 5HT-1A)
Note. All the “atypical” antipsychotics retain Dopamine D-2 receptor blockade, deliber-
ately add Serotonin 5HT-2A receptor blockade that is more potent than D-2 blockade.
What else they add differs from agent to agent.
clinical profiles of conventional and atypical antipsychotics and in the
side effect profiles of different atypical agents. There is a fair, though
not perfect, correspondence between the pharmacological profiles of the
different antipsychotic agents and their clinical attributes (efficacy and
side effects). Based on a comparison of the receptor-blocking profiles
of the different antipsychotic agents, one can fairly predict similarities
and differences in their clinical attributes (Tables 1–3).
The pharmacological (principally receptor-blocking) profiles of the
five currently available atypical antipsychotic agents are summarized
in Table 1. Pharmacological activities in parentheses refer to weaker,
but clinically relevant, properties. The letter refers to the neurotrans-
mitter (D = dopamine, 5HT = serotonin, ACh = acetylcholine, H =
histamine, NE = norepinephrine) and the number (eg., 1 or 2A) that
follows refers to the receptor of that neurotransmitter. All activities
noted refer to receptor blockade except for the activities described in
parentheses for ziprasidone. As can be seen from the table, all atypi-
cal antipsychotic agents retain the property of dopamine D-2 blockade
(albeit to differing extents) that characterizes the older conventional
agents. All five newer generation antipsychotics add more potent (than
D-2) blockade of one of the serotonin receptors (the 5HT-2A receptor);
in fact, these five agents block the 5HT2A receptor about ten times as
potently as the D2 receptor and this is the one property that differen-
tiates the group of atypical antipsychotics from the older conventional
antipsychotics (12,13,15). In addition to these shared attributes (D-2
blockade and more potent 5HT-2A blockade), the atypicals differ in their
other pharmacological properties.
The likely clinical implications of antagonizing various neurotrans-
mitter receptors are summarized in Table 2 (12,16). All known antipsy-
chotic agents in the world (including the 20 approved antipsychotic
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TABLE 2
Clinical Implications of Blockade of Various Receptors by Antipsy-
chotics
Receptors Possible Benefits Possible Side Effects
Dopamine D2 receptor Antipsychotic effect Extrapyramidal movement
Efficacy on positive disorders (EPS), (dystonia,
symptoms Efficacy Parkinsonism, akathisia,








5HT2A receptors Reduced EPS Sexual disturbances
5HT2C receptors Not definitely known Weight gain
Histamine H1 receptor Not definitely known Sedation, weight gain





a1-Adrenergic receptor Not definitely known Postural hypotension,
dizziness
agents in the U.S.A.) block the dopamine D-2 receptor. Consequently,
D-2 blockade (presumably in the mesolimbic dopamine tract) can
presently be considered as being essential for antipsychotic activity.
Dopamine-2 blockade in the nigrostriatal dopamine system, however,
results in extrapyramidal side effects (EPS) and D2 blockade in the
tubero-infundibular system results in prolactin elevation and related
side effects (menstrual irregularities, sexual dysfunction, gynaecomas-
tia, etc.).
In recent years, the pervasiveness and tightness of D-2 blockade
(rather than mere presence or absence of D-2 blockade) have been re-
lated to the antipsychotic efficacy of antipsychotic agents and their
propensity to cause EPS and prolactin elevation (17,18). It has been
suggested that greater than 60% blockade of D-2 receptors is necessary
for antipsychotic activity, whereas more than 70% blockade results in
prolactin elevation and greater than 80% blockade results in EPS. It has
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also been suggested that tighter blockade of the dopamine D2 receptor
(more difficult for endogenous brain dopamine to displace) results in a
higher risk of EPS.
5HT-2A receptor blockade more potent than D-2 receptor blockade
substantially reduces the risk of EPS associated with such D-2 block-
ade (15). Thus it may be possible to achieve an antipsychotic effect (for
which you need D-2 blockade) without EPS (which D-2 blockade would
cause in the absence of more potent 5HT-2A receptor blockade). This at-
tribute of the newer generation of antipsychotics is believed to explain
their ability to achieve an antipsychotic effect with a much lower risk of
EPS than with conventional agents. The relative risk of EPS with the
various antipsychotic agents at clinically effective doses is perhaps best
explained by a combination of 5HT2A/D2 blockade, pervasiveness and
tightness/looseness of dopamine receptor blockade. The clinical impli-
cations (mainly side effects) of other receptor-blocking properties are
also summarized in Table 2; an effort is made to stay very close to what
we know well without speculation.
Table 3 summarizes how the five atypical agents compare to each
other and typical neuroleptics with regard to various side effects. Anti-
cholinergic side effects (peripheral, cardiac, and central) are explained
by the degree of antimuscarinic anticholinergic activity in-vivo (12,16).
Dizziness and postural hypotension (necessitating dose titration)
are best explained by alpha-1 NE blockade. Sedation is explained
principally by antihistaminic activity, but anticholinergic and D-2
antagonism properties also contribute. Weight gain is best explained
by a combination of 5HT-2C blockade, H-1 blockade, and D-2 blockade.
Factors contributing to EPS and prolactin elevation have been consid-
ered previously; other side effects are not easily explained on the basis
of known pharmacological activities. Specific side effects are now briefly
considered along with the relative propensity of various newer genera-
tion agents to cause them.
Acute Extrapyramidal Side Effects (EPS)
By definition, all “atypical” antipsychotics are less likely than conven-
tional antipsychotics to cause EPS; in fact, that is how they got the
“atypical” label. There are, however, differences between various atyp-
ical agents with regard to the ease and consistency with which EPS
can be avoided at clinically effective doses. Among the five currently
available newer generation antipsychotics, the hierarchy of EPS risk is
risperidone> olanzapine= ziprasidone> quetiapine> clozapine. Clin-
ically, these differences are most relevant in vulnerable populations,
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(elderly, adolescents, patients with Parkinson’s disease with psychosis,
etc.). These differences also become relevant to optimal dosing of these
agents (Table 4) so as to obtain an acceptable antipsychotic effect with-
out EPS as also in circumstances when an atypical agent is used con-
currently with a conventional agent (here, the analogy of Parkinson’s
disease with psychosis is useful). Since the absence of EPS principally
contributes to the many benefits of atypicality (Figure 2), it is essen-
tial that EPS be avoided. Furthermore, EPS should be avoided without
use of anticholinergic antiparkinsonian medication, as most benefits
(eg, cognitive advantage, lower risk of tardive dyskinesia, etc.) are lost
when these agents are utilized.
Weight Gain and Related Side Effects
Weight gain is emerging as one of the most significant side effects asso-
ciated with atypical antipsychotic therapy (19–21). Weight gain is asso-
ciated with an increased risk of diabetes mellitus and hyperlipidemia
(all associated with an increase risk of coronary heart disease); and
there are increasing reports of these “complications” in patients with
schizophrenia receiving atypical antipsychotics. The relative propen-
sity to cause weight gain among the newer generation antipsychotics is
clozapine > olanzapine > risperidone = quetiapine > ziprasidone; the
average weight gain with one-year treatment ranges from 33 lbs (cloza-
pine) to 2 lbs (ziprasidone) with olanzapine (25 lbs) and risperidone/
quetiapine (4–8 lbs) in between. There are increasing reports of new-
onset diabetes mellitus, exacerbation of existing diabetes, and cases of
diabetic ketoacidosis in association with atypical antipsychotic treat-
ment (particularly with clozapine and olanzapine). Although it is pre-
mature to conclude that olanzapine, clozapine, or other atypical agents
cause diabetes, attention to this issue is warranted.
QTc Prolongation
In the past decade, the issue of prolongation of the QTc (QT interval on
the EKG corrected for heart-rate) has received increasing scrutiny from
the Food and Drug Administration (FDA) and five different medica-
tions have been withdrawn from the market and several others have re-
ceived different kinds of product warnings because of this issue (22,23).
Prolongation of the QTc (generally indicative of slowed ventricular re-
polarization) has been associated with an increased risk of Toursade
de Pointes (a polymorphic ventricular tachycardia), which in turn has
been associated with other potentially fatal ventricular arrhythmias.
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Whereas all the newer generation antipsychotics (like the older gen-
eration conventional agents) prolong the QTc interval, they do so to
different extents. Several methods are employed to rate-correct the QT
interval, and therefore there are several QTc’s; however, among the
newer generation agents, the usual hierarchy of QTc prolongation is
ziprasidone = clozapine > quetiapine ≥ risperidone ≥ olanzapine. The
QTc prolongation associated with olanzapine, risperidone, and queti-
apine are in the range of that associated with haloperidol (which has
hitherto been considered to cause clinically irrelevant QT prolongation).
The QTc prolongation associated with ziprasidone is intermediate be-
tween that of haloperidol and thioridazine. The precise relevance of the
degree of QTc prolongation associated with the various atypical agents
is unclear, and no increase in rates of Toursades or sudden cardiac
deaths has been found with any of these agents.
Sedation
All newer generation antipsychotics and conventional agents are se-
dating (hence the old term “tranquilizer”), but cause different degrees
of sedation. Among the newer generation agents, the hierarchy of pro-
ducing sedation is clozapine > quetiapine > olanzapine > risperidone >
ziprasidone. Sedation is most prominent in the early stages of antipsy-
chotic therapy and some degree of tolerance develops over time.
Prolactin Elevation and Related Side Effects
The older “conventional” antipsychotic agents all increased levels of the
hormone, prolactin; among the newer generation agents, risperidone
alone consistently increases prolactin levels. While increased prolactin
levels have been associated with sexual dysfunction, menstrual irreg-
ularities, etc., an increased occurrence of these clinical symptoms in
risperidone-treated (in contrast to other atypical-treated) patients has
not been clearly demonstrated. It is suggested that prolactin-related
clinical side effects occur in about 25–30% of patients with increased
levels of prolactin (24,25).
Hypotension
All antipsychotic agents cause hypotension, particularly postural hy-
potension, although they do so to different extents. Among the newer
generation antipsychotics, the hierarchy of producing hypotension is
clozapine > quetiapine > risperidone > olanzapine = ziprasidone.
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Hypotension tends to be most prominent in the early stages of treat-
ment with tolerance developing over time. Adequate hydration mit-
igates the problem of hypotension, although agents that are associ-
ated with more hypotension are best titrated up to their target dose
(over 2–3 days for risperidone and quetiapine, and over 1–2 weeks for
clozapine).
Anticholinergic Side Effects
Because of varying degrees of intrinsic anticholinergic activity, different
atypical antipsychotic agents cause varying degrees of anticholinergic
side effects. The spectrum of anticholinergic side effects include pe-
ripheral symptoms (dryness of mouth, constipation, urinary retention,
etc.), cardiovascular symptoms (tachycardia, increased risk of tachy-
arrhythmias, etc.) and cognitive symptoms (impaired learning and
memory) (26,27). Among the newer generation antipsychotic agents,
the hierarchy of anticholinergic side effects is clozapineÀ olanzapine>
quetiapine ≥ risperidone/ziprasidone. It should be noted, however, that
except for clozapine, the magnitude of anticholinergic side effects as-
sociated with the atypicals is much smaller than that associated with
benztropine and trihexyphenidyl (oral anticholinergic agents used to
prevent and treat antipsychotic-associated EPS). It is therefore crit-
ical that EPS be avoided without concomitant use of anticholinergic
agents.
Miscellaneous Other Side Effects
A variety of other side effects have been reported in association with
atypical antipsychotic treatment; these include elevated liver enzymes,
acute pancreatitis, priapism, tardive dyskinesia, neuroleptic malignant
syndrome, special sense adverse effects, etc. It is unclear if there are
meaningful differences in rates of these side effects with the different
atypical agents. It appears that rates of neuroleptic malignant syn-
drome and tardive dyskinesia are lower with newer-generation in con-
trast with conventional antipsychotic agents.
IN SUMMARY
Since the multiple benefits associated with atypical antipsychotic treat-
ment are principally related to their ability to achieve an optimal an-
tipsychotic effect without producing EPS, it is critical that atypical
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agents be dosed in such a way that they produce an optimal antipsy-
chotic effect without EPS and without the need for adjunctive anti-
cholinergic treatment to treat such EPS. Although there is significant
heterogeneity in treatment response and the optimal dose varies across
individual patients, we have a fair body of evidence that guides appro-
priate dosing for the vast majority of patients. In the treatment of young
adults suffering from schizophrenia, appropriate initial target doses for
the five atypical agents and the maximum dose likely to benefit a major-
ity of patients are summarized in Table 4. Appropriate dose ranges in
TABLE 4
The Atypical Antipsychotics (Summary)
Clozapine, Risperidone, Olanzapine, Quetiapine, Ziprasidone
1. Equivalent efficacy in treating psychotic symptoms in various disorders
– clozapine is more effective in patients refractory to conventional
antipsychotics
– no other convincing evidence of differential efficacy among various
atypical agents
– broader spectrum of efficacy (negative, cognitive, and mood symptoms)
2. Significantly less likely than conventional agents to cause
extrapyramidal side effects
– ease and consistency with which efficacy without EPS is achieved
varies from atypical to atypical
3. Multiple benefits (fewer negative symptoms, better cognition, less
depression, lower risk of tardive dyskinesia) accompany this EPS
advantage of atypical agents
– Dosing is key to achieving this profile of optimal efficacy without EPS
– Recommendations about dosing in young adult schizophrenia patients
Agent Initial dose to go up to Maximum dose likely to be beneficial
Clozapine: 400 mg/day 500 mg/day (level 370–500 ng/ml)
Risperidone: (2!) 3–4 mg per day 6 mg/day
Olanzapine: 15–20 mg per day 30–40 mg/day! (outside FDA
recommendations)
Quetiapine: 400–600 mg per day 800–1200 mg/day (>800 mg/day
outside FDA guidelines)
Ziprasidone: 100–120 mg per day 160–200 mg/day? (>160 mg/day
outside FDA guidelines)
– lower doses in children, elderly, and other vulnerable populations
– lower doses in patients with other diagnoses
4. Differ in propensity to cause other side effects (sedation, weight gain
and related adverse effects, hypotension, cardiovascular, prolactin
elevation and related adverse effects, etc.)
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children, the elderly, and other vulnerable populations would be lower.
Similarly, appropriate doses to treat nonschizophrenic conditions would
also be lower than indicated.
Because of their superior adverse effect profiles, atypical agents are
recommended over conventional antipsychotics. Since there is no evi-
dence of differential efficacy between different first-line atypical agents,
efficacy is not a factor in choosing between them. Differences in side
effect profiles, however, allow selection of the initial antipsychotic based
on the need to avoid the most undesirable side effects in each individual
patient.
In summary, schizophrenia treatment involves the judicious use of
multiple treatment modalities, of which pharmacology is among the
most important. Primary goals of treatment are the rapid and com-
plete control of active psychosis, avoidance of functional deterioration,
and prevention of relapse; secondary objectives include minimizing side
effects and optimizing function. Although numerous medication options
are available, and treatment must be tailored to individual situations,
the newer atypical antipsychotics have significant advantages in rou-
tine use over conventional agents. Despite their higher cost, the benefits
of patient acceptance, reduced risk of side effects, and broader spectrum
of activity make their use compelling. To maximize the benefits of atyp-
ical antipsychotics, the dose of medication should be carefully adjusted
to achieve as complete a remission of psychotic symptoms as possible,
without accompanying EPS or the use of anticholinergic medications
to treat or prevent EPS (Figure 2). Differences in side effect profiles of
atypical agents allow individualization of treatment. If dosing a partic-
ular newer generation antipsychotic to achieve an adequate antipsy-
chotic effect with acceptable tolerability is unsuccessful, a change to
an alternative atypical antipsychotic is indicated and will generally in-
clude a very gradual cross titration, during which the patient is never
free of “antipsychotic cover.”
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